MARKET

GNMX

Aevi Genomic Med
GNMX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.3309
-
-3.1067
12,892,716.43
News
Financial
Releases
Corp Actions
Analysis
Profile
CERC: Data from CDG-FIRST Trial Upcoming
Zacks Small Cap Research · 03/19 13:50
Done deal: Maryland biopharm firm completes acquisition of Aevi Genomic Medicine
American City Business Journals · 02/04 18:31
Cerecor and Aevi Genomic Medicine Complete Merger
GlobeNewswire · 02/03 21:15
Aevi Genomic Medicine, Inc. (GNMX): Hedge Fund Sentiment Unchanged
Insider Monkey · 12/22/2019 22:08
CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…
Zacks Small Cap Research · 12/13/2019 14:50
Aevi Genomic to be acquired in a deal valued at up to $22.6 million
American City Business Journals · 12/09/2019 19:34
Merger Arbitrage Mondays - Thoma Bravo's Acquisition Of Instructure Includes A Go-Shop Provision
Seeking Alpha - Article · 12/09/2019 14:11
Cerecor To Acquire Aevi Genomic Medicine For $16.1M In An All-Stock Transaction
Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered
Benzinga · 12/05/2019 13:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNMX. Analyze the recent business situations of Aevi Genomic Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNMX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 4.96M
% Owned: 6.38%
Shares Outstanding: 77.71M
TypeInstitutionsShares
Increased
3
1.43M
New
6
137.62K
Decreased
7
587.98K
Sold Out
3
378.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Non-Executive Chairman
Sol Barer
President/Chief Executive Officer/Director
Michael Cola
Chief Financial Officer
Michael McInaw
Chief Scientific Officer
Garry Neil
Director
Matthew Bayley
Independent Director
Eugene Bauer
Independent Director
Alastair Clemow
Independent Director
Barbara Duncan
Independent Director
Joseph Grano
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aevi Genomic Med stock information, including NASDAQ:GNMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNMX stock methods without spending real money on the virtual paper trading platform.